Date:2/7/2011

S. were $1.013 billion, representing a decrease of 0.2 percent compared with the prior-year period, or a decrease of 0.3 percent on a foreign currency-neutral basis. International revenue growth was negatively impacted by about 3 percentage points related to the flu pandemic in fiscal year 2010. Revenues reflected continued strength in emerging markets, which was partially offset by a decline in sales in Europe.

Company Reaffirms Previously Communicated Fiscal Year 2011 Guidance The Company continues to estimate that reported revenues for the full fiscal year 2011 will increase about 4 percent compared to fiscal year 2010.  The Company also continues to expect reported diluted earnings per share from continuing operations for fiscal year 2011 to be between $5.45 and $5.55, an increase of approximately 11 to 13 percent over fiscal year 2010.  Diluted earnings per share from continuing operations for fiscal year 2011 are expected to increase 10 to 12 percent over adjusted diluted earnings per share from continuing operations, excluding specified item, of $4.94 for fiscal year 2010.  The specified item represents a 2010 non-cash charge of $0.04 cents per share related to healthcare reform impacting Medicare Part D reimbursements.

Conference Call InformationA conference call regarding BD's first quarter results and its expectations for the full fiscal year 2011 will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 10:00 a.m. (ET) Tuesday, February 8, 2011.  The related slides are available concurrent with this press release at www.bd.com/investors.  The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international) through the close of business on Tuesday, February 15, 2011, a
'/>"/>

SOURCE BD (Becton, Dickinson and Company) Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
2. BD Announces Agreement to Acquire Accuri Cytometers, Inc.
3. Misonix Announces Completion of Product Registrations in Key Latin American Markets
4. ConvaTec Announces New Appointments to Leadership Team
5. Medivation Announces Participation in 13th Annual BIO CEO & Investor Conference
6. Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements
7. Fairleigh Dickinson University Announces Partnership with Medco Health Solutions, Inc. for New School of Pharmacy
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results
9. Dendreon Announces Exercise and Closing of Overallotment Option
10. Hospira Announces FDA Approval of Topotecan Injection
11. BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc.